Equity
€198,182 ▼ 58.1%
SEMAPHAR paid out €377,224 in dividends. That is 370% of the 2025 profit.
SEMAPHAR
Lifetime
11 annual accounts with figures on one time axispeak €154,902 (2025)
€154,902▲ 618%
lowest -€6,151 (2024)
€101,958▲ €108,109
peak €479,599 (2023)
€198,182▼ 58.1%
€381,222▲ 130×
Board1 name since 2015
1 directorWILLEMS Paul Wilhelm
Documentsfilings and deeds
09-03-2026144 days before the deadline
2025micro format
Gross margin from €21,560 to €154,902Back to profit: €101,958Dividend €377,224Equity from €473,448 to €198,182Debts from €2,929 to €381,222Cash from €67,417 to €135,593
Key points
from the 2025 annual accountsResult
€101,958 €101,958
Back in profit in 2025, after a loss of €6,151 in 2024.
Turnover
≈ €390,000 estimated
The micro format states no turnover.
Debts
€381,222 ▲ 130×
Debts rose by €378,294 in 2025. A dividend stands under other debts on the balance sheet date until it is paid.
Liquidity
1.05 was 97.48 in 2024
Short-term debts rose from €2,929 to €381,222.
Filings
11 annual accounts since 2015
The last five annual accounts were filed 56 to 144 days before the end of the period.
Checked score
92
Excellent
Financially stronger than 35% of micro companies in research and development (NACE 72)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.1% across 932 companies (NACE 72, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%lowest value
01-2025: < 0.1%● unchanged vs 12-2024lowest value
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: 0.1%▲ +0.1 percentage points vs 06-2025
08-2025: < 0.1%▼ -0.1 percentage points vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: 0.1%▲ +0.1 percentage points vs 10-2025highest value
12-2025: < 0.1%▼ -0.1 percentage points vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
lowers risk
Size: total assets €579,404
Figures for financial year 2025 (filed on 10-03-2026)
Liquidity: current ratio 1.05, cash €135,593
Sector: Scientific research and development (NACE 72)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro). It does better than 35% of them on solvency, 22% on liquidity, 71% on profitability and 14% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 17,811 companies had the same profile as SEMAPHAR has now. Each dot stands for 45 companies, two years later.
96.5%
were still trading
3.2%
stopped another way
0.3%
went bankrupt
That fits the bankruptcy probability of SEMAPHAR itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 17,811 companies, not a prediction for SEMAPHAR. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €18,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.05 (97.48 in 2024), below the usual 1.5. Short-term debt is 65.8% and cash 23.4% of total assets. 65.8% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
5 signals, none raises the risk
Five signals.
lowers riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 09-03-2026, 144 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
144 days early
2024
56 days early
2023
71 days early
2022
77 days early
2021
82 days early
2020
60 days early
2019
52 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 77 days before the deadline. In the sector (NACE 72), the median for financial year 2024 was 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 15 May (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0568568963
Change of role: WILLEMS Paul Wilhelm, from manager to director
“toute activité de gestion immobilière” (deed in French) · Director discharge: WILLEMS Paul Wilhelm · General meeting of 27-09-2023 · Gazette deed
Incorporation
published on 13-01-2015 · Gazette deed
First establishment
Rue Francourt (Lat.) 31, Jodoigne
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| SEMAPHAR Jodoigne | €579,404 | €154,902 | 34.2% | - |
| Dokter Sara Van Soom, huisarts Edegem | €477,219 | €187,919 | 8.9% | - |
| ViaNova Rixensart | €768,240 | €475,656 | 13.3% | - |
| CASC8 Keerbergen | €822,069 | €207,114 | 74.4% | - |
| OPIS BELGIUM Brussels | €630,008 | €334,290 | 21.4% | 2 |
| CannIbite Kontich | €503,922 | €60,311 | 31.3% | - |
| CERTOR Mechelen | €505,224 | €101,531 | 96.3% | - |
These companies have the same main activity as SEMAPHAR: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €477,000 and €822,000, founded between 2012 and 2016.
Official details
Source: KBO- Status
- Active since 09-01-2015Normal situation
- Activity
- Research and development on biotechnologyNACE 72101and 3 others
- Establishment unit
- 2.238.778.3111370 Jodoigne, since 09-01-2015
- Financial year end
- 31 December
- Peppol
- Reachable since 26-11-2025
Annual accounts 2025
- €579,404▲ 21.6%
- Filing
- Filed on 09-03-2026, 144 days before the end of the filing period
Insights on SEMAPHAR
SEMAPHAR files the micro format. That format states no turnover. The gross margin rose from €107,722 in 2015 to €154,902 in 2025.
The balance sheet grew most from 2016 to 2018 through fixed assets.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about SEMAPHAR
- What is the company number of SEMAPHAR?
- The company number of SEMAPHAR is 0568.568.963. The VAT number is the same number with BE in front: BE 0568.568.963.
- Where is SEMAPHAR based?
- The registered office is at Rue Francourt (Lat.) 31, 1370 Jodoigne.Company details
- What does SEMAPHAR do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of SEMAPHAR?
- SEMAPHAR is a private limited company (BV).
- When was SEMAPHAR founded?
- SEMAPHAR was founded on 09-01-2015.
- Is SEMAPHAR still active?
- Yes, SEMAPHAR is an active enterprise in the KBO register.
- What is the turnover of SEMAPHAR?
- The turnover in financial year 2025 is ≈ €390,000. This figure is estimated from the gross margin of €154,902 and 2,203 comparable companies of the same size. It probably lies between €260,000 and €600,000. It is a rough estimate.Financials
- Is SEMAPHAR profitable?
- In financial year 2025, SEMAPHAR made a profit of €101,958.
- Where can I find the annual accounts of SEMAPHAR?
- SEMAPHAR filed 11 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of SEMAPHAR due?
- SEMAPHAR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.